Texas Heart Institute and BiVACOR achieve milestone with total artificial heart implantation

FHS
July 25, 2024
4:31 pm

The Texas Heart Institute (THI) and BiVACOR, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024.

Over 1 million race records show East Africans as fastest in 50-km ultra-marathons

A study in Scientific Reports analyzed the age and country of elite 50-km ultra-marathon runners, revealing that the fastest athletes are from African countries, with

June 17, 2024

Postmenopausal hormone therapy use declines amidst risk-benefit concerns

A study reveals a sharp decline in menopausal hormone therapy use among U.S. women, highlighting disparities across racial and ethnic groups over two decades.

October 2, 2024

Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall

What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and

April 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.